Table 1.
Clinico-pathological characteristics of the patients
| All, n (%) | Low-TIL, n (%) | High-TIL, n (%) | P value | |
|---|---|---|---|---|
| Total population | 278 (100) | 251 (90) | 27 (10) | |
| Age (years) | ||||
| ≥50 | 133 (48) | 121 (91) | 12 (9) | |
| <50 | 145 (52) | 130 (90) | 15 (10) | 0.87 |
| Clinical stage at diagnosis | ||||
| I–II | 138 (52) | 121 (88) | 17 (12) | |
| III | 129 (48) | 119 (92) | 10 (8) | 0.3 |
| Unknown | 1 | 1 | 0 | |
| Histological type | ||||
| Ductal | 253 (93) | 226 (89) | 27 (11) | |
| Lobular | 5 (2) | 5 (100) | 0 | |
| Other | 15 (5) | 15 (100) | 0 | 0.31 |
| Unknown | 5 | 5 | 0 | |
| Grade (at diagnosis) | ||||
| 1–2 | 36 (17) | 32 (89) | 4 (11) | |
| 3 | 176 (83) | 159 (90) | 17 (10) | 0.97 |
| Unknown | 66 | 60 | 6 | |
| Nodal status after neoadjuvant chemotherapy | ||||
| Neg | 128 (46) | 110 (86) | 18 (14) | |
| Pos | 148 (54) | 139 (94) | 9 (6) | 0.04 |
| Unknown | 2 | 2 | 0 | |
| Residual tumor size | ||||
| ≤2 cm | 126 (47) | 104 (82.5) | 22 (17.5) | |
| >2 cm | 142 (53) | 137 (96.5) | 5 (3.5) | 0.0003 |
| Unknown | 10 | 10 | 0 | |
| Neoadjuvant chemotherapy | ||||
| Anthra-based | 133 (48) | 121 (91) | 12 (9) | |
| Anthra + Tax-based | 125 (45) | 115 (92) | 10 (8) | 0.4 |
| Other | 20 (7) | 15 (75) | 5 (25) | |
| Anthra + Tax either before or after surgery | ||||
| Yes | 173 (62) | 161 (93) | 12 (7) | |
| No | 105 (38) | 90 (86) | 15 (14) | 0.07 |
| Number of neoadjuvant chemotherapy cycles | ||||
| <6 | 124 (46) | 111 (45) | 13 (48) | |
| ≥6 | 148 (54) | 134 (55) | 14 (52) | 0.93 |
Anthra, anthracycline; Tax, Taxane.